

A.

	Pts	Events	HR	95% CI	P
Univariate analyses based on all patients					
Age (yrs)	83	51	1.018	0.998 – 1.039	.074
PS 2-3? (0=No, 1=Yes)	83	51	1.39	0.50 – 3.87	.55
Male? (0=No, 1=Yes)	83	51	1.89	1.00 – 3.55	.039
Nonwhite? (0=No, 1=Yes)	82	50	1.79	0.89 – 3.60	.12
WBC (1000/mm ³)	83	51	0.996	0.987 – 1.006	.43
Peripheral blasts (%)	74	44	1.011	1.001 – 1.021	.031
Peripheral blasts (1000/mm ³)	74	44	1.011	0.999 – 1.023	.11
Periph. lymphocytes (%)	81	50	0.991	0.979 – 1.002	.091
Periph. lymphs (1000/mm ³)	81	50	0.985	0.963 – 1.007	.098
Periph. neutrophils (%)	82	51	0.995	0.978 – 1.011	.51
Periph. neuts (1000/mm ³)	82	51	0.946	0.876 – 1.021	.034
Hemoglobin (g/dL)	83	51	0.891	0.795 – 0.997	.041
Platelets (1000/mm ³)	83	51	0.996	0.992 – 1.001	.11
Marrow blasts (%)	69	41	1.000	0.985 – 1.015	.98
Cytogenetically evaluable? (0=No,1=Yes)	83	51	0.77	0.44 – 1.36	.38
Analyses based on cytogenetically evaluable patients					
t(9;22)/ <i>BCR/ABL1</i> ? (0=No,1=Yes)	55	32	4.80	2.05 – 11.2	.0009
Heterogeneity among 4 karyotype categories (P = 0.0099)					
Normal diploid	15	7	1.00	Referent	Ref.
t(9;22)/ <i>BCR/ABL1</i>	9	9	5.84	2.02 – 16.9	.0011
Other unfavorable ¹	8	4	1.27	0.37 – 4.35	.70
Miscellaneous	23	12	1.36	0.53 – 3.47	.52

¹ Other unfavorable is defined by the presence of -7, +8, and 11q23/*MLL* gene rearrangements.

Abbreviations: Pts = number of patients included in analysis, Events = number of relapses or deaths in remission, HR = estimates hazard ratio, CI = confidence interval, P = 2-sided p-value, PS = Zubrod performance status.

B.

	Estimated Hazard Ratio	95% Confidence Interval	Two-sided P-value
Model 1. DFS by karyotype category and age			
Normal diploid	1.00	Referent	Referent
t(9;22)/ <i>BCR/ABL1</i>	5.70	1.85 – 17.6	0.0025
Other unfavorable ¹	1.27	0.37 – 4.34	0.71
Miscellaneous	1.34	0.52 – 3.49	0.54
Test for heterogeneity among four karyotype categories			0.0088
Age (yrs)	1.002	0.977 – 1.027	0.89
Model 2. DFS by karyotype category and sex			
Normal diploid	1.00	Referent	Referent
t(9;22)/ <i>BCR/ABL1</i>	5.82	2.02 – 16.8	0.0011
Other unfavorable ¹	1.24	0.36 – 4.34	0.73
Miscellaneous	1.37	0.54 – 3.49	0.51
Test for heterogeneity among four karyotype categories			0.0041
Female	1.00	Referent	Referent
Male	1.09	0.49 – 2.40	0.84

¹ Other unfavorable is defined by the presence of -7, +8, and 11q23/*MLL* gene rearrangements.

² Based on N=XXX patients with known peripheral blast counts.

	Estimated Hazard Ratio	95% Confidence Interval	Two-sided P-value
Model 3. DFS by karyotype category and peripheral blasts (%) ²			
Normal diploid	1.00	Referent	Referent
t(9;22)/ <i>BCR/ABL1</i>	5.33	1.70 – 16.7	.0041
Other unfavorable ¹	1.29	0.37 – 4.48	.68
Miscellaneous	1.15	0.43 – 3.07	.78
Test for heterogeneity among four karyotype categories			0.015
Peripheral blasts (%) ²	1.009	0.994 – 1.024	0.25

Model 4. DFS by karyotype category and hemoglobin (%)			
Normal diploid	1.00	Referent	Referent
t(9;22)/ <i>BCR/ABL1</i>	5.85	2.02 – 16.9	.0011
Other unfavorable ¹	1.25	0.37 – 4.29	.72
Miscellaneous	1.59	0.60 – 4.27	.36
Test for heterogeneity among four karyotype categories			.0058
Hemoglobin (g/dL)	0.897	0.742 – 1.084	.26

¹ Other unfavorable is defined by the presence of -7, +8, and 11q23/*MLL* gene rearrangements.

² Based on N=49 patients with known peripheral blast counts.